

## Special Issue on Novel Breakthroughs in Parkinson's Disease Treatment

# CALL FOR PAPERS

Parkinson's disease (PD), the second most common neurodegenerative disorder, is a disease of the central nervous system. As the population ages, PD is expected to impose an increasing social and economic burden. PD is caused by the progressive impairment or deterioration of dopaminergic neurons in the substantia nigra; however, the exact pathogenic mechanisms underlying selective dopaminergic cell loss are still not well understood. Currently, none of the attempts to establish therapies for PD have succeeded. Many challenges exist, such as a complex multisystem disorder, poor understanding of the key molecular events, absence of reliable and relevant animal models, and lack of effective biomarkers of disease stage and progression.

Promising new active compounds establish new therapeutic strategies that overcome limitations of neuroprotection and the selective stimulation of various dopamine receptors. There is also an increased emphasis on targeted therapy, disease management therapy, decreasing dyskinesia, and reducing side-effects.

The upcoming special issue will cover all aspects of this prevalent neurodegenerative disease, illustrating the broader picture and highlighting an exciting portfolio of breakthroughs spanning drugs, cells, vaccines, devices, genetics, care, and behavior. We invite investigators to contribute original papers or state-of-the-art reviews describing recent findings in the field of PD pathophysiology, therapy, and epidemiology. All contributions will undergo a rapid, fair, and concise review process to minimize publication times.

Potential topics include but are not limited to the following:

- ▶ Isolation, identification, and characterization of novel drugs
- ▶ Drug resistance and its pharmacological management
- ▶ Prions, vaccines, and growth factors
- ▶ Alternative treatments: deep brain stimulation, lesioning, radiosurgery, and radiofrequency ablation
- ▶ Noninvasive treatment, such as transcranial magnetic stimulation and focused ultrasound
- ▶ The future perspective of PD treatment

Authors can submit their manuscripts through the Manuscript Tracking System at <http://mts.hindawi.com/submit/journals/pd/nbpd/>.

### Lead Guest Editor

Nir Qvit, Stanford University, Stanford, USA

*nir.qvit@gmail.com*

### Guest Editors

Amnon Sintov, Ben-Gurion University of the Negev, Be'er Sheva, Israel

*asintov@bgu.ac.il*

Danilo Medinas, University of Chile, Santiago, Chile

*dmedinas@med.uchile.cl*

### Manuscript Due

Friday, 4 August 2017

### First Round of Reviews

Friday, 27 October 2017

### Publication Date

Friday, 22 December 2017